Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Daniella Licht
Daniella Licht, Givat Shmuel IL
| Patent application number | Description | Published |
|---|---|---|
| 20090111892 | Rasagiline Orally Disintegrating Compositions - This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions. | 04-30-2009 |
| 20090162432 | Stable laquinimod preparations - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. | 06-25-2009 |
| 20100008983 | Rasagiline soft gelatin capsules - Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties. | 01-14-2010 |
| 20100189787 | Delayed release rasagiline citrate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
| 20100189788 | Delayed release rasagiline base formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
| 20100189790 | Delayed release rasagiline formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
Daniella Licht, Ramat Ilan IL
| Patent application number | Description | Published |
|---|---|---|
| 20090181086 | Rasagiline formulations, their preparation and use - Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties. | 07-16-2009 |
| 20100189791 | Delayed release rasagiline malate formulation - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 07-29-2010 |
Daniella Licht, Givat Shamuel IL
| Patent application number | Description | Published |
|---|---|---|
| 20100160273 | CONTROLLED DELIVERY SYSTEM OF ANTIFUNGAL AND KERATOLYTIC AGENTS FOR LOCAL TREATMENT OF FUNGAL INFECTIONS OF THE NAIL AND SURROUNDING TISSUES - A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifungal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent or combination thereof. The composition may further include an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof. | 06-24-2010 |
Daniella Licht US
| Patent application number | Description | Published |
|---|---|---|
| 20110251235 | STABLE LAQUINIMOD PREPARATIONS - The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier. | 10-13-2011 |
Daniella Licht, Kiriat-Ono IL
| Patent application number | Description | Published |
|---|---|---|
| 20110301234 | FORMULATIONS OF LADOSTIGIL TARTRATE - The invention relates to a pharmaceutical composition of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water. The composition is typically in a solid oral form which upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL. | 12-08-2011 |